11/16/2026 | Press release | Distributed by Public on 11/16/2026 14:35
Management's Discussion and Analysis of Financial Conditions and Results of Operations
The following is management's discussion and analysis of financial condition and results of operations and is provided as a supplement to the accompanying unaudited condensed financial statements and notes to help provide an understanding of our financial condition, results of operations and cash flows during the periods included in the accompanying unaudited condensed financial statements.
In this Quarterly Report on Form 10-Q, "Company," "the Company," "us," and "our" refer to Quarta-Rad, Inc., a Delaware corporation, unless the context requires otherwise.
We intend the following discussion to assist in the understanding of our financial position and our results of operations for the three and nine months ended September 30, 2026 and 2025. You should refer to the Financial Statements and related Notes in conjunction with this discussion.
Results of Operations
General
We were incorporated under the laws of the State of Delaware on November 29, 2011, with a fiscal year end of December 31. We were initially formed to distribute and sell radiation detection devices and related products to consumers and businesses in North America.
Beginning in 2013, we purchased products from Quarta-Rad, Ltd. ("QRR"), a company located in Russia, and shipped products to third-party online retailers and resellers for distribution. In recent periods, the Company has reduced its focus on its historical radiation detection product line and has shifted its primary business focus toward software development and AI-driven technologies.
During April 2020, we acquired Quarta-Rad USA, Inc., a Delaware corporation, as a wholly owned subsidiary. No consideration was paid for the shares. The purpose of the acquisition was to separate certain operations into a separate entity. Quarta-Rad USA was dissolved in 2022.
During December 2020, we acquired Sellavir, Inc. ("Sellavir"), an AI software company focused on advanced analytics, image processing, and call center software solutions. Sellavir's technology platform is designed to assist organizations in analyzing video and operational data through proprietary AI technologies.
Sellavir has developed CenterEye, a software platform intended to simplify the use and management of cloud-based call center systems. CenterEye is designed to enhance call center operations through AI-driven analytics, automation, and operational monitoring capabilities.
Prior to April 2024, our chief executive officer and director, Victor Shvetsky, and our former director and president, Alexey Golovanov, were our only employees. In April 2024, Mr. Golovanov resigned from the Company.
The Company's current focus is the continued development and commercialization of CenterEye and related AI-driven software solutions. Management is actively pursuing opportunities in the United States, Japan, and other international markets. The Company currently generates revenue primarily through relationships with its Japanese reseller associated with Sellavir's software and development services.
Substantially all of the Company's revenue is generated by Sellavir from software development and consulting services provided to Star Systems Corporation ("STAR"), a Japanese entity of which the Company's Chief Executive Officer and majority shareholder is also the majority shareholder. STAR accounted for $39,000 of the Company's $39,906 consolidated revenue for the three months ended September 30, 2026 (98%) and $127,000 of $129,618 for the nine months then ended (98%).
Because this revenue is derived from an entity under common control, the pricing and volume of these arrangements have not been established through arm's-length negotiation and may not be indicative of the results the Company would achieve with unaffiliated customers. The Company has no contractual commitment from STAR with respect to future volumes, and STAR may reduce or discontinue its engagement of Sellavir at any time. The loss of this relationship would eliminate substantially all of the Company's revenue. Investors should not assume that historical revenue from STAR is indicative of the Company's ability to generate revenue from unaffiliated customers.
Our administrative office is located at 1201 N. Orange St., Suite 700, Wilmington, DE 19801.
Our business strategy is focused on expanding the development, marketing, and deployment of CenterEye and related technologies. We aim to enhance call center efficiency and customer engagement through AI-driven solutions while pursuing strategic relationships with businesses requiring advanced customer service and operational analytics platforms.
Sellavir Consulting
We expanded our operations through the acquisition of Sellavir in December 2020. Sellavir leverages its expertise in neural networks and artificial intelligence technologies to provide customized software development and AI-related services to clients. These services include image processing applications, operational analytics, and call center software solutions.
Our business model is focused on identifying customer-specific operational needs and developing software solutions to address those needs. Currently, the Company's revenue associated with Sellavir operations is generated primarily through its Japanese reseller relationships.
The Company acquired Sellavir to:
● leverage Sellavir's AI capabilities in connection with future technology initiatives;
● expand operations beyond the Company's historical radiation detection product business; and
● pursue opportunities within the call center software industry through the development and commercialization of CenterEye.
CenterEye is intended to be offered as a subscription-based software platform, which management believes may provide recurring revenue opportunities in future periods. Sellavir began recognizing revenue related to call center software operations during 2024.
In January 2026, our subsidiary Sellavir entered into an Independent Software Vendor Partner Agreement with Genesys Cloud Services, Inc., under which Sellavir became a participant in the Genesys AppFoundry Program. The agreement does not provide for any minimum revenue, exclusivity, or guaranteed continuation, and we have generated no revenue under the agreement during the nine months ended September 30, 2026
The Company has two operating segments through the operations of Quarta-Rad and Sellavir. Net loss for the three months ended September 30, 2026, is comprised of:
| Quarta Rad | Sellavir | Total | ||||||||||
| Sales | $ | 906 | $ | 39,000 | $ | 39,906 | ||||||
| Cost of goods sold | 348 | 24,080 | 24,428 | |||||||||
| Gross profit | 558 | 14,920 | 15,478 | |||||||||
| Expenses: | ||||||||||||
| General & administrative | 8,954 | 25,794 | 34,748 | |||||||||
| Professional and consulting fees | 13,200 | 8,000 | 21,200 | |||||||||
| Operating expenses | 22,154 | 33,794 | 55,948 | |||||||||
| Net loss from operations | (21,596 | ) | (18,874 | ) | (40,470 | ) | ||||||
| Other expense - foreign currency transaction loss | (2,826 | ) | (2,826 | ) | ||||||||
| Other income - interest - related party | - | 802 | 802 | |||||||||
| Unrealized gain on investments | - | 1 | 1 | |||||||||
| Net loss | $ | (21,596 | ) | $ | (20,897 | ) | $ | (42,493 | ) | |||
The Company has two operating segments through the operations of Quarta-Rad and Sellavir. Net loss for the nine months ended September 30, 2026, is comprised of:
| Quarta Rad | Sellavir | Total | ||||||||||
| Sales | $ | 2,618 | $ | 127,000 | $ | 129,618 | ||||||
| Cost of goods sold | 348 | 86,940 | 87,288 | |||||||||
| Gross profit | 2,270 | 40,060 | 42,330 | |||||||||
| Expenses: | ||||||||||||
| General & administrative | 32,335 | 101,786 | 134,121 | |||||||||
| Professional and consulting fees | 45,600 | 28,230 | 73,830 | |||||||||
| Operating expenses | 77,935 | 130,016 | 207,951 | |||||||||
| Net loss from operations | (75,665 | ) | (89,956 | ) | (165,621 | ) | ||||||
| Other expense - foreign currency transaction loss | - | (18,241 | ) | (18,241 | ) | |||||||
| Other income - interest - related party | - | 2,406 | 2,406 | |||||||||
| Net loss | $ | (75,665 | ) | $ | (105,791 | ) | $ | (181,456 | ) | |||
Management's Plan to Address Going Concern Considerations
The Company has experienced recurring operating losses, primarily due to limited revenues. The Company's current financial conditions and recurring losses raise substantial doubt about its ability to continue as a going concern.
Management intends to fund operations through existing cash balances, revenues generated from operations, related party support, and, if necessary, additional capital raises or strategic financing arrangements. There can be no assurance that such financing will be available on acceptable terms or at all.
Consolidated Totals:
Three months ended September 30, 2026 compared with the three months ended September 30, 2025
Revenues. Our revenues decreased $22,563, or 36.12%, to $39,906 for the three months ended September 30, 2026, compared with $62,469 for the three months ended September 30, 2025. The reduction was primarily attributable to the phase-out of Quarta-Rad sales and the timing of consulting projects and revenue recognized by Sellavir.
Cost of Goods Sold. Our cost of goods sold decreased $9,254, or 27.47%, to $24,428 for the three months ended September 30, 2026, compared with $33,682 for the three months ended September 30, 2025. The decrease was primarily due to the decrease of revenue.
Operating Expenses. Our operating expenses decreased $38,799, or 40.95%, to $55,948 for the three months ended September 30, 2026, compared with $94,747 for the three months ended September 30, 2025. General and administrative expenses were $34,748 versus $75,046, and professional and consulting fees were $21,200 versus $19,701. The decrease is primarily attributable to stock compensation in Sellavir.
Net Loss. Our net loss decreased $24,148, or 36.24%, to $42,493 for the three months ended September 30, 2026, compared with $66,641 for the three months ended September 30, 2025. The decrease was primarily attributable to the decrease in operating expenses.
QUARTA-RAD
Three months ended September 30, 2026, compared with the three months ended September 30, 2025
Revenues. Our revenues decreased $1,563, or 63.30%, to $906 for the three months ended September 30, 2026, compared with $2,469 for the three months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.
Cost of Goods Sold. Our cost of goods sold decreased $626, or 64.27%, to $348 for the three months ended September 30, 2026, compared with $974 for the three months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.
Operating Expenses. Our operating expenses decreased $7,575, or 25.48%, to $22,154 for the three months ended September 30, 2026, compared with $29,729 for the three months ended September 30, 2025. General and administrative expenses were $8,954 versus $10,028, and professional and consulting fees were $13,200 versus $19,701. The decrease was primarily attributable to the phase out of Quarta-Rad's overhead expenses.
Net Loss. Our net loss decreased $6,638, or 23.51%, to $21,596 for the three months ended September 30, 2026, compared with $28,234 for the three months ended September 30, 2025. The decrease was primarily attributable to the decrease in operating expenses.
SELLAVIR
Three months ended September 30, 2026, compared with the three months ended September 30, 2025
Revenues. Our revenues decreased $21,000, or 35.00%, to $39,000 for the three months ended September 30, 2026, compared with $60,000 for the three months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue.
Cost of Goods Sold. Our cost of goods sold decreased $8,628, or 26.38%, to $24,080 for the three months ended September 30, 2026, compared with $32,708 for the three months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue recognition.
Operating Expenses. Our operating expenses decreased $31,224, or 48.02%, to $33,794 for the three months ended September 30, 2026, compared with $65,018 for the three months ended September 30, 2025. The decrease is primarily attributable to the decrease in stock based compensation recognized in 2025.
Net Loss. Our net loss decreased $17,510, or 45.59%, to $20,897 for the three months ended September 30, 2026, compared with $38,407 for the three months ended September 30, 2025. The decrease was primarily attributable to the decrease in operating expenses.
Consolidated Totals:
Nine months ended September 30, 2026 compared with the nine months ended September 30, 2025
Revenues. Our revenues decreased $33,068, or 20.33%, to $129,618 for the nine months ended September 30, 2026, compared with $162,686 for the nine months ended September 30, 2025. The reduction was primarily attributable to the phase-out of Quarta-Rad sales and the timing of consulting projects and revenue recognized by Sellavir.
Cost of Goods Sold. Our cost of goods sold decreased $10,243, or 10.50%, to $87,288 for the nine months ended September 30, 2026, compared with $97,531 for the corresponding period in 2025. The decrease was primarily due to the decrease in sales.
Operating Expenses. Our operating expenses decreased $99,629, or 32.39%, to $207,951 for the nine months ended September 30, 2026, compared with $307,580 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in administrative expenses and stock based compensation.
Net Loss. Our net loss decreased $34,689, or 16.05%, to $181,456 for the nine months ended September 30, 2026, compared with $216,145 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in administrative expenses.
QUARTA-RAD
Nine months ended September 30, 2026, compared with the nine months ended September 30, 2025
Revenues. Our revenues decreased $5,068, or 65.94%, to $2,618 for the nine months ended September 30, 2026, compared with $7,686 for the nine months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.
Cost of Goods Sold. Our cost of goods sold decreased $3,461, or 90.86%, to $348 for the nine months ended September 30, 2026, compared with $3,809 for the nine months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.
Operating Expenses. Our operating expenses decreased $52,037, or 40.04%, to $77,935 for the nine months ended September 30, 2026, compared with $129,972 for the nine months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad's overhead expenses.
Net Loss. Our net loss decreased $50,430, or 39.99%, to $75,665 for the nine months ended September 30, 2026, compared with $126,095 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in administrative expenses.
SELLAVIR
Nine months ended September 30, 2026, compared with the nine months ended September 30, 2025
Revenues. Our revenues decreased $28,000, or 18.06%, to $127,000 for the nine months ended September 30, 2026, compared with $155,000 for the nine months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue recognition.
Cost of Goods Sold. Our cost of goods sold decreased $6,782, or 7.24%, to $86,940 for the nine months ended September 30, 2026, compared with $93,722 for the nine months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue recognition.
Operating Expenses. Our operating expenses decreased $47,592, or 26.80%, to $130,016 for the nine months ended September 30, 2026, compared with $177,608 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in stock based compensation recognized in 2025.
Net Loss. Our net loss increased $15,741, or 17.48%, to $105,791 for the nine months ended September 30, 2026, compared with $90,050 for the nine months ended September 30, 2025. The increase in net loss was primarily attributable to lower revenues and the unfavorable change in foreign currency transaction results, partially offset by a decrease in operating expenses.
Liquidity and Capital Resources. During the three and nine months ended September 30, 2026, we used cash for operating expenses from cash on hand and consulting revenue from Sellavir.
Our total assets were $352,290 and $413,511 as of September 30, 2026 and December 31, 2025, respectively. Cash was $19,955 and $72,909, respectively. The related party note, including its current portion, and accrued interest totaled $300,343 and $316,178, respectively. The Thai corporation is an entity of which our Chief Executive Officer serves as Chief Executive Officer and holds a minority interest.
That note is secured by undeveloped land located in Thailand. Under amendments entered into in January 2024 and May 2025, principal payments are deferred until April 1, 2027, with quarterly payments thereafter through April 1, 2031, and interest is payable at maturity. The Company has received no principal payments since April 2024 and ceased recognizing interest income on the note as of March 31, 2025 due to uncertainty regarding collectability. Accordingly, this asset is not available to fund operations in the near term, and there can be no assurance as to the amount or timing of any recovery.
Our working capital deficit was $334,628 and $216,617 as of September 30, 2026 and December 31, 2025, respectively. Current assets were $56,583 and $72,912, while current liabilities were $391,211 and $289,529, respectively. The deficit increased $118,011. Stockholders' deficit was $38,921 at September 30, 2026, compared with equity of $123,982 at December 31, 2025.
Net cash used in operating activities was $52,954 and $29,913 for the nine months ended September 30, 2026 and 2025, respectively, an increase of $23,041, or 77.02%.
There were no cash flows from investing activities for the nine months ended September 30, 2026 and 2025.
There were no cash flows from financing activities for the nine months ended September 30, 2026 and 2025. The cash flow statements classify changes in related party payables within operating activities.
The Company had no formal long-term lines of credit or other bank financing arrangements as of September 30, 2026.
The Company has no current plans for the purchase or sale of any plant or equipment.
The Company has no current plans to make any changes in the number of employees
The Company's financial assets include significant receivables from related parties and other counterparties, including a related party note denominated in Thai baht, accrued interest receivable, and a long-term trade receivable. Collection of these amounts is subject to counterparty credit risk and, in the case of the Thai baht-denominated note, foreign currency exchange rate fluctuations. The Company evaluates these receivables for expected credit losses under ASC 326. Delays in collection or deterioration in the financial condition of the counterparties could adversely affect the Company's liquidity and financial position.
Impact of Inflation
The Company believes that inflation has had a negligible effect on operations over the past quarter
Capital Expenditures
The Company expended no amounts on capital expenditures for the three and nine months ended September 30, 2026.
Plan of Operation
Our business strategy has evolved from primarily marketing radiation detection products to focusing on the development and commercialization of CenterEye, our proprietary AI-driven call center software platform. We aim to enhance call center efficiency, operational visibility, and customer engagement through advanced analytics, automation, and monitoring solutions. While we continue to maintain our online presence related to our historical product lines, management's primary efforts are directed toward software development, marketing, and establishing strategic relationships with businesses requiring advanced customer service and operational analytics platforms.
While we continue to maintain our website at www.quartarad.com, we have increased our focus on Sellavir's operations and related marketing efforts as part of our long-term business strategy.
During December 2020, Quarta-Rad acquired Sellavir, Inc., a Delaware corporation under common control, as a wholly owned subsidiary in exchange for 333,333 shares of common stock. The value of the shares issued was approximately $170,000 on the date of issuance.
Sellavir is an AI software and analytics company focused on advanced operational analytics, image processing, and call center software technologies. Sellavir's platform utilizes artificial intelligence ("AI") and proprietary technologies designed to assist organizations in analyzing operational and video-based data to improve business performance and customer engagement.
Sellavir, Inc., our wholly-owned subsidiary, is currently focused on the continued development and commercialization of CenterEye, a call center software platform that leverages AI and advanced analytics to improve call center operations. CenterEye is designed to provide real-time insights, operational metrics, monitoring capabilities, and customer engagement tools intended to improve efficiency and customer satisfaction.
Management is actively pursuing opportunities in Japan, the United States, and other international markets through reseller relationships and direct marketing efforts.
We intend to implement the following tasks within the next twelve months:
Software Development:
We intend to continue investing in the development and enhancement of CenterEye to meet the evolving needs of the call center industry. This includes adding new features, improving user experience, enhancing reporting and analytics capabilities, and improving scalability and platform functionality.
Marketing:
(Estimated cost $25,000 - $75,000). We intend to increase our marketing efforts to generate additional leads, reseller opportunities, and customer relationships for CenterEye and related software solutions. Marketing efforts may include digital advertising, website enhancements, promotional materials, and attendance at industry-related events and conferences
Partnerships and Client Acquisition:
(Estimated cost $20,000). We intend to pursue strategic relationships with call center operators, technology providers, and resellers. Management intends to focus on pilot projects, reseller arrangements, and initial software deployments designed to demonstrate the effectiveness of CenterEye and support future recurring revenue opportunities.
Historical Product Operations:
While the Company continues to maintain limited activities associated with its historical radiation detection product business, management's primary operational focus has shifted toward AI-driven software and analytics solutions.
Our management does not currently anticipate the need to hire additional full-time employees over the next three months, as the services currently provided by our officers, directors, and independent contractors are expected to be sufficient for current operations. As our software development and commercialization activities expand, we may engage additional independent contractors or consultants to support development, marketing, operational, or business development activities.
We currently do not own material equipment that we intend to sell in the near future, do not have any off-balance sheet arrangements, and have not paid material expenses on behalf of our directors outside the ordinary course of business
Off-Balance Sheet Arrangements
None.
Forward Looking Statements
This Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2 of Part I of this report include forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (collectively, the "Reform Act"). The Reform Act provides a safe harbor for forward-looking statements to encourage companies to provide prospective information about themselves so long as they identify these statements as forward-looking and provide meaningful cautionary statements identifying important factors that could cause actual results to differ from the projected results. All statements, other than statements of historical fact that we make in this Quarterly Report on Form 10-Q, are forward-looking. The words "anticipates," "believes," "expects," "intends," "will continue," "estimates," "plans," "projects," the negative of these terms and similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean the statement is not forward-looking.
Forward-looking statements involve risks, uncertainties or other factors which may cause actual results to differ materially from the future results, performance or achievements expressed or implied by the forward-looking statements. These statements are based on our management's beliefs and assumptions, which in turn are based on currently available information. Certain risks, uncertainties or other important factors are detailed in this Quarterly Report on Form 10-Q and may be detailed from time to time in other reports we file with the Securities and Exchange Commission, including on Forms 8-K and 10-K.
We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict all those risks, nor can we assess the impact of all those risks on our business or the extent to which any factor may cause actual results to differ materially from those contained in any forward-looking statement. We believe these forward-looking statements are reasonable. However, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Further, forward-looking statements speak only as of the date they are made, and unless required by law, we expressly disclaim any obligation or undertaking to update publicly any of them considering new information or future events.
Critical Accounting Policies
Our condensed financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, and Note 3 to the Condensed and Consolidated Financial Statements in this Form 10-Q.
The Company's receivables consist primarily of amounts due from related parties, long-term notes receivable, and trade accounts receivable. These balances include receivables from STAR, a note receivable denominated in Thai baht, and a long-term trade receivable. Accounts and notes receivable are stated at amortized cost, net of any applicable allowance for credit losses.
Management evaluates the collectibility of these receivables in accordance with ASC 326, Financial Instruments-Credit Losses, considering factors such as historical collection experience, the financial condition and creditworthiness of the counterparties, contractual payment terms, current economic conditions, and reasonable and supportable forecasts. Changes in estimated credit losses are recognized in earnings through adjustments to the allowance for credit losses. Receivables deemed uncollectible are written off against the allowance.
A reserve for sales returns and allowances is considered immaterial and, as a result, there was no reserve for sales returns and allowances at September 30, 2026 and December 31, 2025, respectively.